Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemoradiotherapy in high-risk locally advanced cervical cancer
ChiCTR2100044326Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Cervical Cancer (CC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Disease-free survival time. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100044326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044326.